Evidence map›Paper›PMID 28259153›Full record

ArticleBMC cancer2017

Altering calcium influx for selective destruction of breast tumor.

Han-Gang Yu, Sarah McLaughlin, Mackenzie Newman, Kathleen Brundage, Amanda Ammer, Karen Martin, James Coad

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Cancer: A bioelectric disease?Clinical and translational medicine · 2026
    Review
  2. Bioelectricity in dental medicine: a narrative review.Biomedical engineering online · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. PGRMC1 Inhibits Progesterone-Evoked Proliferation and CaInternational journal of molecular sciences · 2020
    Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Han-Gang YuDepartment of Physiology and Pharmacology, West Virginia University, One Medical Center Drive, Morgantown, WV, 26506, USA. hyu@hsc.wvu.edu.ORCID 0000-0001-6838-8310
Sarah McLaughlinMary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, 26506, USA.
Mackenzie NewmanDepartment of Physiology and Pharmacology, West Virginia University, One Medical Center Drive, Morgantown, WV, 26506, USA.
Kathleen BrundageMary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, 26506, USA.
Amanda AmmerMary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, 26506, USA.
Karen MartinMary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, 26506, USA.
James CoadDepartment of Pathology, West Virginia University, Morgantown, WV, 26506, USA.
West Virginia University · US

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI GARY O RANKIN · 2012 to 2026
$61.1M
THE ROLE OF HEF1 PROTEIN IN INVASION OF METASTATIC BREAST CANCERP20RR016440 · NCRR · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2001 to 2010
$22.8M
West Virginia Flow Cytometry Core FacilityP30GM103488 · NIGMS · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2012 to 2016
$4.8M
COBRE FOR SIGNAL TRANSDUCTION AND CANCER PHASE IIIP30RR032138 · NCRR · WEST VIRGINIA UNIVERSITY · PI GIBSON, LAURA F. · 2011 to 2011
$1.1M
Special Becton Dickinson Fortessa Flow CytometerS10OD016165 · OD · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2013 to 2013
$384k
NCRR NIH HHS P20 RR016440NCRR NIH HHS P30 RR032138NIGMS NIH HHS P20 GM103434NIGMS NIH HHS P30 GM103488NIGMS NIH HHS U54 GM104942NIH HHS S10 OD016165
6 · The paper itself

Abstract

backgroundHuman triple-negative breast cancer has limited therapeutic choices. Breast tumor cells have depolarized plasma membrane potential. Using this unique electrical property, we aim to develop an effective selective killing of triple-negative breast cancer.

methodsWe used an engineered L-type voltage-gated calcium channel (Cec), activated by membrane depolarization without inactivation, to induce excessive calcium influx in breast tumor cells. Patch clamp and flow cytometry were used in testing the killing selectivity and efficiency of human breast tumor cells in vitro. Bioluminescence and ultrasound imaging were used in studies of human triple-negative breast cancer cell MDA-MB-231 xenograft in mice. Histological staining, immunoblotting and immunohistochemistry were used to investigate mechanism that mediates Cec-induced cell death.

resultsActivating Cec channels expressed in human breast cancer MCF7 cells produced enormous calcium influx at depolarized membrane. Activating the wild-type Cav1.2 channels expressed in MCF7 cells also produced a large calcium influx at depolarized membrane, but this calcium influx was diminished at the sustained membrane depolarization due to channel inactivation. MCF7 cells expressing Cec died when the membrane potential was held at -10 mV for 1 hr, while non-Cec-expressing MCF7 cells were alive. MCF7 cell death was 8-fold higher in Cec-expressing cells than in non-Cec-expressing cells. Direct injection of lentivirus containing Cec into MDA-MB-231 xenograft in mice inhibited tumor growth. Activated caspase-3 protein was detected only in MDA-MB-231 cells expressing Cec, along with a significantly increased expression of activated caspase-3 in xenograft tumor treated with Cec.

conclusionsWe demonstrated a novel strategy to induce constant calcium influx that selectively kills human triple-negative breast tumor cells.

Indexed as

Electric Stimulation TherapyAdenocarcinomaAnimalsCalciumCalcium Channels, L-TypeCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceTriple Negative Breast NeoplasmsXenograft Model Antitumor AssaysCalciumCalcium Channels, L-TypeBioelectricityBreast cancerCalcium channelCaspase-3Selective killingTriple-negative

Identifiers

PMID28259153
PMCPMC5336649
OpenAlexW2592850813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.